Acción RTSL RAPID THERAPEUTIC SCIENCE LABORATORIES, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate
Instrumento Inactivo

Otros idiomas Rapid Therapeutic Science Laboratories, Inc. Other OTC

Acciones

RTSL

US7534311052

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Rapid Therapeutic Science Laboratories : Change in Certifying Accountants - Form 8-K
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Rapid Therapeutic Science Laboratories, Inc. Auditor Raises 'Going Concern' Doubt
White House Office of Management and Budget review on Cannabis-Derived Products confirms Rapid Therapeutic Science Laboratories’ Long-Term Strategy
Rapid Therapeutic Science Laboratories Updates Patents
RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Rapid Therapeutic Science Laboratories File S1 and completes Mid-Year Strategy Review
RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits (form 8-K)
Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.35 million in funding
RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
Rapid Therapeutic Science Laboratories to Attend the Respiratory Drug Delivery (RDD) 2022 Conference
Rapid Therapeutic Science Laboratories Announces 1-for-25 Reverse Stock Split
RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción RTSL
  4. Acción RTSL
  5. Noticias Rapid Therapeutic Science Laboratories, Inc.
  6. Otros idiomas